** Disc Medicine's shares down 1.9% to $59.35 premarket as biopharma firm looks to raise equity
** Watertown, Massachusetts-based firm late Tues $200 mln offering consisting of stock and pre-funded warrants
** Co plans to use net offering proceeds to fund research and clinical development of its product candidates, to support potential commercialization of its treatment for erythropoietic protoporphyria $(EPP.UK)$, a
rare disease that causes painful sensitivity to light
** IRON shares on Tues rose nearly 4% to close at $60.52 after co received from US FDA for
** Jefferies, Leerink, Stifel and Cantor jt bookrunners for the equity offering
** Through Tues, IRON shares down 4.5% to begin 2025. Stock's 1-yr high is $77.60 (Mar 4) and 1-yr low is $25.60 (Apr 1)
(Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。